Adjuvant Ipilimumab Shows Sustained Efficacy at 7 Years for Stage III Melanoma

Silas Inman @silasinman
Published: Saturday, Jun 01, 2019
Alexander M. M. Eggermont, MD, PhD
Alexander Eggermont, MD, PhD
Adjuvant ipilimumab (Yervoy) elicited a 25% reduction in the risk of recurrence or death compared with placebo for patients with surgically resected high-risk, stage III melanoma, according to an updated analysis of findings from the phase III EORTC 18071 study.1

Although it may be limited by safety, Page noted that an ongoing study is examining the combination of nivolumab and ipilimumab as an adjuvant treatment for patients with melanoma. This phase III study, known as CheckMate-915, is comparing nivolumab plus ipilimumab with nivolumab alone after complete resection of stage III or IV melanoma. The study enrolled 1943 patients, with primary results anticipated in November 2020 (NCT03068455).
  1. Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial. J Clin Oncol. 2019; 37 (suppl; abstr 2512).
  2. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824-1835.
<<< 2019 ASCO Annual Meeting
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication